Eli Lilly garnered widespread praise Tuesday for launching discounted versions of its blockbuster obesity drug Zepbound. Before, the treatment had only been sold in injectable pens for a list price of $1,060 per month, but now, Lilly will also sell starter doses in vials that cost up to $549 a month, “expanding supply and access,” the company said.
In Lilly’s press release, one patient group called it “an innovative solution that brings us closer to making equitable care a reality.” And even President Biden chimed in on X, crediting his administration’s work on pressuring drugmakers to lower prices.
But a deeper look at the announcement suggests the new offering may not expand access as much as the company indicates.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
